A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor for Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer at High Risk of Recurrence
Clinical trial NCT06830720 · RECRUITING
Trial details
- NCT number
- NCT06830720
- Sponsor
- Novartis Pharmaceuticals
- Status
- RECRUITING
- Study type
- OBSERVATIONAL
- Start date
- 2025-02-20
- Primary completion
- 2030-06-30
- Enrollment
- 3250
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.